Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessCompaniesVidaza generic doing well for us; market share is increasing: Shilpa Medicare

    Vidaza generic doing well for us; market share is increasing: Shilpa Medicare

    The US Food and Drug Administration (US FDA) has given an all clear to Shilpa Medicare‘s formulation manufacturing facility at Jadcherla in Telangana. In an interview to CNBC-TV18, Vishnukant Bhutada, MD of the company spoke about the same.

    CNBC-TV18
    March 19, 2018 / 10:51 IST

    The US Food and Drug Administration (US FDA) has given an all clear to Shilpa Medicare's formulation manufacturing facility at Jadcherla in Telangana. In an interview to CNBC-TV18, Vishnukant Bhutada, MD of the company spoke about the same.

    We have done 32 filings from this plant including our customer filing, said Bhutada.

    Talking about Raichur unit, he said we have submitted response for Raichur unit observations to US FDA.

    He further said that Vidaza generic is doing well for the company and we are getting more market share from this molecule.

    For entire interview, watch accompanying video.

    CNBC-TV18
    first published: Mar 19, 2018 10:26 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347
    CloseOutskill Genai